353 related articles for article (PubMed ID: 17534814)
1. Ocular symptoms and signs with preserved and preservative-free glaucoma medications.
Jaenen N; Baudouin C; Pouliquen P; Manni G; Figueiredo A; Zeyen T
Eur J Ophthalmol; 2007; 17(3):341-9. PubMed ID: 17534814
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication.
Pisella PJ; Pouliquen P; Baudouin C
Br J Ophthalmol; 2002 Apr; 86(4):418-23. PubMed ID: 11914211
[TBL] [Abstract][Full Text] [Related]
3. [Clinical tolerance of antiglaucoma eyedrops with and without a preservative. Results of an unpublished survey in Europe].
Levrat F; Pisella PJ; Baudouin C
J Fr Ophtalmol; 1999 Mar; 22(2):186-91. PubMed ID: 10327349
[TBL] [Abstract][Full Text] [Related]
4. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
[TBL] [Abstract][Full Text] [Related]
5. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
6. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].
Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372
[TBL] [Abstract][Full Text] [Related]
7. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
[TBL] [Abstract][Full Text] [Related]
8. Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensive Therapy.
Roberti G; Agnifili L; Berardo F; Riva I; Figus M; Manni G; Quaranta L; Oddone F
Adv Ther; 2018 May; 35(5):686-696. PubMed ID: 29687335
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication.
Ghosh S; O'Hare F; Lamoureux E; Vajpayee RB; Crowston JG
Clin Exp Ophthalmol; 2012; 40(7):675-81. PubMed ID: 22394358
[TBL] [Abstract][Full Text] [Related]
10. [Managing treatment side effects: the respective roles of the active ingredient and the preservative].
Aptel F; Denis P; Baudouin C
J Fr Ophtalmol; 2011 Jun; 34(6):409-12. PubMed ID: 21511364
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-1beta tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers.
Manni G; Centofanti M; Oddone F; Parravano M; Bucci MG
Am J Ophthalmol; 2005 Jan; 139(1):72-7. PubMed ID: 15652830
[TBL] [Abstract][Full Text] [Related]
12. [Effects of preservatives in anti-glaucoma agents on the ocular surface].
Potop V
Oftalmologia; 2009; 53(2):92-6. PubMed ID: 19697847
[TBL] [Abstract][Full Text] [Related]
13. Risk factors to develop ocular surface disease
in treated glaucoma or ocular hypertension patients.
Rossi GC; Pasinetti GM; Scudeller L; Raimondi M; Lanteri S; Bianchi PE
Eur J Ophthalmol; 2013; 23(3):296-302. PubMed ID: 23335308
[TBL] [Abstract][Full Text] [Related]
14. Topical preservative-free ophthalmic treatments: an unmet clinical need.
Figus M; Agnifili L; Lanzini M; Brescia L; Sartini F; Mastropasqua L; Posarelli C
Expert Opin Drug Deliv; 2021 Jun; 18(6):655-672. PubMed ID: 33280452
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications.
Lazreg S; Merad Z; Nouri MT; Garout R; Derdour A; Ghroud N; Kherroubi R; Meziane M; Belkacem S; Ouhadj O; Baudouin C; Tiar M
J Fr Ophtalmol; 2018 Dec; 41(10):945-954. PubMed ID: 30477719
[TBL] [Abstract][Full Text] [Related]
16. PRESERVATIVES FROM THE EYE DROPS AND THE OCULAR SURFACE.
Coroi MC; Bungau S; Tit M
Rom J Ophthalmol; 2015; 59(1):2-5. PubMed ID: 27373107
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of preservative-free and preserved diclofenac and preserved ketorolac eyedrops after cataract surgery.
Maca SM; Amon M; Findl O; Kahraman G; Barisani-Asenbauer T
Am J Ophthalmol; 2010 May; 149(5):777-84. PubMed ID: 20152959
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma.
Rouland JF; Traverso CE; Stalmans I; Fekih LE; Delval L; Renault D; Baudouin C;
Br J Ophthalmol; 2013 Feb; 97(2):196-200. PubMed ID: 23203707
[TBL] [Abstract][Full Text] [Related]
19. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.
Baudouin C
Acta Ophthalmol; 2008 Nov; 86(7):716-26. PubMed ID: 18537937
[TBL] [Abstract][Full Text] [Related]
20. [Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent].
Mlčáková E; Mlčák P; Karhanová M; Langová K; Marešová K
Cesk Slov Oftalmol; 2016; 72(4):120-127. PubMed ID: 27860477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
